Bone Biologics (BBLG) Free Cash Flow (2013 - 2025)
Bone Biologics (BBLG) posted quarterly Free Cash Flow of -$723612.0 for Q4 2025, up 46.54% year-over-year from -$493806.4 in Q4 2024, and down 22.36% quarter-over-quarter from -$591384.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Free Cash Flow (2013 - 2025) Analysis & Trends
Bone Biologics (BBLG) has reported Free Cash Flow for 14 consecutive years, with -$723612.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Free Cash Flow rose 46.54% year-over-year to -$723612.0; the TTM figure through Dec 2025 stood at -$2.7 million (up 34.54% YoY), while the FY2025 annual figure was -$2.7 million, up 34.54% from the prior year.
- Free Cash Flow eased to -$723612.0 in Q4 2025 per BBLG's latest filing, from -$591384.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at -$127983.0 in Q1 2021 and bottomed at -$3.6 million in Q2 2023.
- Historically, Free Cash Flow has averaged -$1.1 million across 5 years, with a median of -$792195.5 in 2022.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 944.03% — and 2024, when it surged 77.61%.
- Bone Biologics' Free Cash Flow stood at -$186852.0 in 2021, then tumbled by 944.03% to -$2.0 million in 2022, then decreased by 3.45% to -$2.0 million in 2023, then soared by 32.93% to -$1.4 million in 2024, then soared by 46.54% to -$723612.0 in 2025.
- Business Quant data shows BBLG's Free Cash Flow at -$723612.0 in Q4 2025, -$591384.0 in Q3 2025, and -$458879.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -700,000.00 |
| Sep 30, 2025 | -614,996.00 |
| Jun 30, 2025 | -458,879.00 |
| Mar 31, 2025 | -926,125.00 |
| Dec 31, 2024 | -1.35 Mn |
| Sep 30, 2024 | -572,162.00 |
| Jun 30, 2024 | -895,865.00 |
| Mar 31, 2024 | -1.30 Mn |
| Dec 31, 2023 | -2.02 Mn |
| Sep 30, 2023 | -2.56 Mn |
| Jun 30, 2023 | -3.63 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | -1.95 Mn |
| Sep 30, 2022 | -395,279.00 |
| Jun 30, 2022 | -360,064.00 |
| Mar 31, 2022 | -860,779.00 |
| Dec 31, 2021 | -186,852.00 |
| Sep 30, 2021 | -277,770.00 |
| Jun 30, 2021 | -635,981.00 |
| Mar 31, 2021 | -127,983.00 |